Literature DB >> 35459417

Contribution of Innate Lymphoid Cells in Supplementing Cytokines Produced by CD4+ T Cells During Acute and Chronic SIV Infection of the Colon.

Natasha Ferguson1, Andrew Cogswell1, Edward Barker1.   

Abstract

HIV/SIV (simian immunodeficiency virus) infection leads to a loss of CD4+ T helper (Th) cells in number and function that begins during the acute phase and persists through the chronic phase of infection. In particular, there is a drastic decrease of Th17 and Th22 cells in the HIV/SIV-infected gastrointestinal (GI) tract as a source of interleukin (IL)-17 and IL-22. These cytokines are vital in the immune response to extracellular pathogens and maintenance of the GI tract. However, innate lymphoid cells (ILCs) are a source of IL-17 and IL-22 during the early stages of an immune response in mucosal tissue and remain vital cytokine producers when the immune response is persistent. Here, we wanted to determine whether ILCs are a source of IL-17 and IL-22 in the SIV-infected colon and could compensate for the loss of Th17 and Th22 cells. As a control, we evaluated the frequency and number of ILCs expressing interferon-gamma (IFNγ) and tumor necrosis factor-alpha (TNFα). We determined the frequency and number of cytokine expressing ILC subsets and T cell subsets within leukocytes from the colons of uninfected as well as acute and chronic SIV-infected colons without in vitro mitogenic stimulation. In the present study, we find that: (1) the frequency of IL-22, IFNγ, and TNFα but not IL-17 producing ILCs is increased in the acutely infected colon and remains high during the chronically infected colon relative to cytokine expressing ILCs in the uninfected colon, (2) ILCs are a significant source of IL-22, IFNγ, and TNFα but not IL-17 when CD4+ T lymphocytes in the gut lose their capacity to secrete these cytokines during SIV infection, and (3) the changes in the cytokines expressed by ILCs relative to CD4+ T cells in the infected colon were not due to increases in the frequency or number of ILCs in relation to T lymphocytes found in the tissue.

Entities:  

Keywords:  HIV/SIV pathogenesis; acute infection; gastrointestinal tract; immune response; inflammation; innate immunity; innate lymphoid cells; mucosal immunology

Mesh:

Substances:

Year:  2022        PMID: 35459417      PMCID: PMC9514600          DOI: 10.1089/AID.2022.0007

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  76 in total

1.  Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity.

Authors:  Christopher R Weber; David R Raleigh; Liping Su; Le Shen; Erika A Sullivan; Yingmin Wang; Jerrold R Turner
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 2.  Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases.

Authors:  Gunjan Kak; Mohsin Raza; Brijendra K Tiwari
Journal:  Biomol Concepts       Date:  2018-05-30

3.  The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding.

Authors:  Amanda M Marchiando; Le Shen; W Vallen Graham; Karen L Edelblum; Carrie A Duckworth; Yanfang Guan; Marshall H Montrose; Jerrold R Turner; Alastair J M Watson
Journal:  Gastroenterology       Date:  2011-01-13       Impact factor: 22.682

4.  Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection.

Authors:  Kristina Abel; David M Rocke; Barinderpal Chohan; Linda Fritts; Christopher J Miller
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells.

Authors:  Jenny Mjösberg; Jochem Bernink; Korneliusz Golebski; Julien J Karrich; Charlotte P Peters; Bianca Blom; Anje A te Velde; Wytske J Fokkens; Cornelis M van Drunen; Hergen Spits
Journal:  Immunity       Date:  2012-10-11       Impact factor: 31.745

6.  Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection.

Authors:  M Kader; X Wang; M Piatak; J Lifson; M Roederer; R Veazey; J J Mattapallil
Journal:  Mucosal Immunol       Date:  2009-07-01       Impact factor: 7.313

7.  IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue.

Authors:  J M Leung; M Davenport; M J Wolff; K E Wiens; W M Abidi; M A Poles; I Cho; T Ullman; L Mayer; P Loke
Journal:  Mucosal Immunol       Date:  2013-05-22       Impact factor: 7.313

8.  Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen.

Authors:  Tu Anh N Pham; Simon Clare; David Goulding; Julia M Arasteh; Mark D Stares; Hilary P Browne; Jacqueline A Keane; Andrew J Page; Natsuhiko Kumasaka; Leanne Kane; Lynda Mottram; Katherine Harcourt; Christine Hale; Mark J Arends; Daniel J Gaffney; Gordon Dougan; Trevor D Lawley
Journal:  Cell Host Microbe       Date:  2014-09-25       Impact factor: 21.023

9.  Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis.

Authors:  W Vallen Graham; Weiqi He; Amanda M Marchiando; Juanmin Zha; Gurminder Singh; Hua-Shan Li; Amlan Biswas; Ma Lora Drizella M Ong; Zhi-Hui Jiang; Wangsun Choi; Harmon Zuccola; Yitang Wang; James Griffith; Jingshing Wu; Harry J Rosenberg; Yingmin Wang; Scott B Snapper; David Ostrov; Stephen C Meredith; Lawrence W Miller; Jerrold R Turner
Journal:  Nat Med       Date:  2019-04-01       Impact factor: 53.440

10.  Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon.

Authors:  Nobuo Sasaki; Norman Sachs; Kay Wiebrands; Saskia I J Ellenbroek; Arianna Fumagalli; Anna Lyubimova; Harry Begthel; Maaike van den Born; Johan H van Es; Wouter R Karthaus; Vivian S W Li; Carmen López-Iglesias; Peter J Peters; Jacco van Rheenen; Alexander van Oudenaarden; Hans Clevers
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.